Lack of data leads to double NICE no for Novartis's Glivec
This article was originally published in Scrip
Executive Summary
NICE, the National Institute for health and Clinical Excellence in the UK, is set to decline NHS funding for high doses of Novartis's Glivec (imatinib) for treating unresectable and or metastatic gastrointestinal stromal tumors (GIST), it says in preliminary draft guidance published today. It based the decision on a lack of "good quality clinical and cost-effectiveness data".
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.